- Study: Limiting NPs' scope of practice leads to higher costs
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- BD launches needle aimed at diabetics
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
ABBOTT PARK, Ill. — The Food and Drug Administration has approved a new formulation of an injectable drug made by Abbott for prostate cancer.
Abbott announced Monday the approval of a 45-mg, six-month formulation of Lupron Depot (leuprolide acetate) for advanced prostate cancer. Previous formulations have allowed patients to receive the drug every month or every three or four months.
“Lupron Depot is an important treatment option for many patients with advanced prostate cancer,” Abbott VP global pharmaceutical development Eugene Sun said. “Approval of a new six-month formulation means that physicians and patients who have chosen Lupron Depot now have an additional treatment option.”